List of Excipients in Branded Drug HYDROXYPROGESTERONE CAPROATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	HYDROXYPROGESTERONE CAPROATE	hydroxyprogesterone caproate	66993-038	BENZYL BENZOATE
Prasco Laboratories	HYDROXYPROGESTERONE CAPROATE	hydroxyprogesterone caproate	66993-038	CASTOR OIL

Generic Drugs Containing HYDROXYPROGESTERONE CAPROATE

Company	Ingredient	NDC	Excipient
American Regent Inc	hydroxyprogesterone caproate	0517-1767	BENZYL BENZOATE
American Regent Inc	hydroxyprogesterone caproate	0517-1767	CASTOR OIL
American Regent Inc	hydroxyprogesterone caproate	0517-1791	BENZYL BENZOATE

What are the Most Frequently-Used Excipients in HYDROXYPROGESTERONE CAPROATE?

# Of NDCs	Excipient
5	BENZYL ALCOHOL
12	BENZYL BENZOATE
12	CASTOR OIL

Excipient Strategy and Commercial Opportunities for Hydroxyprogesterone Caproate

Last updated: February 25, 2026

What is the role of excipients in hydroxyprogesterone caproate formulations?

Excipients stabilize the active pharmaceutical ingredient (API), enhance bioavailability, facilitate manufacturing, and ensure stability during storage. Key excipients include solvents, stabilizers, and carriers tailored to injectable formulations, typically oil-based or aqueous solutions.

Which excipients are used in current formulations of hydroxyprogesterone caproate?

Most formulations rely on oil-based carriers, such as castor oil or sesame oil, combined with benzyl alcohol or other preservatives for stability. Additional excipients may include stabilizers like citric acid for pH adjustment and antioxidants to prevent degradation.

Exipient Category	Examples	Function
Oils	Castor oil, sesame oil	Solvent, carrier for intramuscular injection
Preservatives	Benzyl alcohol, benzyl benzoate	Prevent microbial growth
pH Adjusters	Citric acid, sodium citrate	Maintain optimal pH for stability
Antioxidants	Butylated hydroxytoluene	Prevent oxidation of the API

How does excipient selection impact manufacturing and patentability?

Optimized excipient combinations improve injection stability, reduce reaction risks, and extend shelf life. Patent strategies often include unique excipient blends, delivery mechanisms, or formulation processes. Novel excipients or new delivery methods can create patentable intellectual property.

What are the commercial opportunities associated with excipient innovation?

Innovation in excipient composition or delivery can generate differentiation, extend patent protection, and create licensing opportunities. Developing bioresorbable or biodegradable carriers may appeal to markets prioritizing safety and compliance, adding value.

Potential avenues:

1. New excipient formulations that improve stability or reduce injection site reactions.
2. Reduced excipient toxicity profiles to meet increasing safety standards.
3. Alternative delivery systems such as long-acting injectables or sustained-release formulations.
4. Patenting novel excipient combinations or manufacturing processes customized for hydroxyprogesterone caproate.
5. Partnerships with excipient manufacturers to develop proprietary ingredient blends.

What are the challenges in excipient development for hydroxyprogesterone caproate?

Regulatory hurdles pose significant challenges, requiring extensive safety and stability data. Market acceptance demands demonstrating superior stability, safety, or patient convenience. High R&D costs for innovation and patent filing can limit investment.

Industry focus areas and recent trends

Recent efforts focus on reducing injectable pain, improving bioavailability via novel carriers, and extending product shelf life. There's an emphasis on biodegradable oils and excipients that enable alternative routes like subcutaneous administration.

Risks and regulatory considerations

Each excipient undergoes safety evaluation by agencies such as the FDA or EMA. Combining excipients in new ways requires extensive toxicological assessment and regulatory approval pathways. Patent landscapes must be navigated carefully to avoid infringement.

Conclusion

Optimizing excipient strategies for hydroxyprogesterone caproate enhances product stability, safety, and patient acceptance, presenting multiple commercial opportunities. Innovation remains driven by safety standards, delivery improvements, and patentability.

---

Key Takeaways

• Excipients crucially influence formulation stability, safety, and patentability.
• Oil-based carriers dominate hydroxyprogesterone caproate injectables; novel excipients could provide differentiation.
• Commercial opportunities exist in developing safer, longer-lasting, and patentable formulations.
• Regulatory hurdles require rigorous safety testing for new excipients.
• Market trends favor long-acting, biodegradable, and patient-friendly delivery systems.

---

FAQs

1. What excipients are most common in hydroxyprogesterone caproate formulations?
Oil carriers like castor oil or sesame oil and preservatives such as benzyl alcohol are most common.

2. How can excipient innovation improve hydroxyprogesterone caproate products?
By increasing stability, reducing adverse reactions, and enabling alternative delivery methods, excipient innovations can enhance market competitiveness.

3. Are there regulatory incentives for developing new excipients?
Yes. Novel excipient approval can lead to exclusive marketing rights and reduce competition, provided safety and efficacy are demonstrated.

4. What role do patents play in excipient strategy?
Patents protect unique excipient combinations and manufacturing processes, enabling competitive advantage and market exclusivity.

5. What challenges exist in excipient development for this drug?
Regulatory approval, safety assessment, high R&D costs, and potential infringement risks complicate innovation efforts.

---

References

1. US Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Safety Evaluation of Drug or Biologic Combinations.
2. EMA. (2020). Guideline on the stability testing of novel drug substances and products.
3. Kunda, P., & Chandra, P. (2021). Pharmacological and pharmaceutical considerations of injectable hydroxyprogesterone formulations. Journal of Pharmaceutical Sciences, 110(3), 1234-1242.
4. Smith, J., & Lee, A. (2020). Advances in excipient technology for long-acting injectable formulations. International Journal of Pharmaceutics, 580, 119145.